Key result
Practical attributable risk better estimates hypercholesterolemia treatment benefit across subgroups than standard risk ratios.
Answers are grounded in this paper and cite their sources.
The value of treating hypercholesterolemia remains controversial despite extensive investigation, in part because of the research orientation of much of the relevant literature. Most published studies report relative measures of risks such as the risk ratio. However, clinicians are concerned with the magnitude of risk, or attributable risk, the difference in risk in those with highest and lowest serum cholesterol levels. Since maximum risk modification is rarely achieved, the attributable risk often overstates the potential benefit of risk factor reduction. A variant of the attributable risk, the practical attributable risk, gives a more realistic estimate of potential benefit. Since clinicians treat individuals and not populations, these measures of risk are most useful if reported for subgroups of patients (eg, men and women, as well as those of varying age). To illustrate these concepts, we review the literature on hypercholesterolemia, report the risk ratio, attributable risk, and practical attributable risk for important patient populations, and discuss the implications for clinical practice.
No takes yet. Share an insight, caveat, or question.
David J. Malenka (1988) conducted a review in Hypercholesterolemia and coronary heart disease. Hypercholesterolemia treatment / serum cholesterol reduction vs. Lowest serum cholesterol levels was evaluated on Coronary heart disease risk (risk ratio, attributable risk, and practical attributable risk). Practical attributable risk provides a more realistic estimate of the clinical benefit of treating hypercholesterolemia across patient subgroups than risk ratios or standard attributable risk.
Synapse has enriched 10 related papers. Consider them for comparative context: